Ocuphire Pharma Results Presentation Deck
2
Disclosures and Forward-Looking Statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements concerning the success and timing of planned future clinical trials for APX3330, timing and
occurrence of an end of phase 2 meeting with the FDA, the potential of a Phase 3 registration path for APX3330, the success and timing of
planned regulatory filings, business strategy, cash runway, scalability, the potential for APX3330 to be the first line of therapy for DR patients, and
the potential market opportunity for the slowing of DR progression. These forward-looking statements are based upon the Company's current
expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i)
the success, costs, and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory
requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks
related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs;
(vi) legislative, regulatory, political and economic developments, (vii) Nyxol partnership may not facilitate the commercialization or market
acceptance of Ocuphire's product candidates; (x) the success and timing of commercialization of any of Ocuphire's product candidates, including
the scalability of Ocuphire's product candidates and (xi) the maintenance of Ocuphire's intellectual property rights. The foregoing review of
important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in
conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be
filed by the Company from time to time with the SEC. All forward-looking statements contained in this presentation speak only as of the date on
which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist
after the date on which they were made.
The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained in or
incorporated by reference into this presentation. Nothing contained in or incorporated by reference into this presentation is, or shall be relied upon
as, a promise or representation by the Company as to the past or future. The Company assumes no responsibility for the accuracy or
completeness of any such information. This presentation also contains estimates and other statistical data made by independent parties and by us
relating to market shares and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not
to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference
purposes only. Such use should not be construed as an endorsement of such products.
OcuphireView entire presentation